Expression Analysis of Protein Inhibitor of Activated STAT in Inflammatory Demyelinating Polyradiculoneuropathy

Abstract

Protein inhibitors of activated STAT (PIAS) are involved in the regulation of the JAK/STAT signaling pathway and have interactions with NF-κB, p73 and p53. These proteins regulate immune responses; therefore dysregulation in their expression leads to several immune-mediated disorders. In the present study, we examined expression of PIAS1-4 in peripheral blood of patients with acute/chronic inflammatory demyelinating polyradiculoneuropathy (AIDP/CIDP) compared with healthy subjects. We demonstrated down-regulation of all PIAS genes in both AIDP and CIDP cases compared with controls. Similarly, comparisons in gender-based groups revealed down-regulation of these gene0s in patients of each gender compared with gender-matched controls. There was no significant difference in expression of PIAS genes between AIDP and CIDP cases. Based on the area under the receiver operating characteristic curves, PIAS1-4 genes could distinguish between inflammatory demyelinating polyradiculoneuropathy and healthy status with accuracy values of 0.87, 0.87, 0.79 and 0.80, respectively. In differentiation between AIDP cases and healthy controls, these values were 0.92, 0.92, 0.83 and 0.86, respectively. Finally, PIAS1-4 genes could discriminate CIDP from healthy status with accuracy values of 0.82, 0.83, 0.75 and 0.75, respectively. The current study underscores the role of PIAS genes in the pathogenesis of inflammatory demyelinating polyradiculoneuropathy and their potential usage as biomarkers.

PIAS family in cancer: from basic mechanisms to clinical applications

“…PIAS protein integrates signals from other signaling pathway to influence the NF-κB activity indirectly. These proteins also interact with p73, a member p53 tumor suppressor family, and play a significant role in its modulating activity through SUMOylation, altering its transcriptional regulator and protein–protein interaction, thereby influenced the cellular processes such as apoptosis and differentiation ( 5 , 30 ). PIAS SUMOylates the p73 α and decreases the p73 transcriptional activity on several genes such as Bax and MDM in HEK293 cells at G1-to-S phase of cell cycle ( 31 ).…”

Repurposing MS immunotherapies for CIDP and other autoimmune neuropathies: unfulfilled promise or efficient strategy?

“…IFN-β is a cytokine secreted by various cells and its immunomodulatory effects are mediated through genetic activation and the Janus Kinases and signal transducer and activator of transcription proteins (JAK-STAT) signalling pathway, which is also involved in CIDP disease activity. 7 – 10 This pathway reduces myeloid dendritic cells in the peripheral blood and prevents antigen presentation by antigen-presenting cells (APCs). 11 IFN-β further induces regulatory T (T reg ) cells and prevents the differentiation of T helper (T h )17 cells.…”